ArticleThe American journal of pathology2004
Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis.
Article in The American journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 97 citations in OpenAlex.
- Hybrid Extracellular Vesicles With Combined Functional Properties From Mesenchymal Stem Cells and Astrocytes for Targeted Neurodegenerative Disease Applications.Journal of extracellular vesicles · 2025Article
- CD105Breast cancer research : BCR · 2025Article
- Rapid and Sensitive Detection of Thrombospondin-2 Using Nanoparticle Sensors for Cancer Screening and Prognosis.Micromachines · 2025Article
- Thrombospondins modulate cell function and tissue structure in the skeleton.Seminars in cell & developmental biology · 2024Review
- Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways.Journal of experimental & clinical cancer research : CR · 2023Article
- Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success.Cellular & molecular immunology · 2023Review
- Periodontal Disease Augments Cardiovascular Disease Risk Biomarkers in Rheumatoid Arthritis.Biomedicines · 2022Article
- Characterization of the plasma proteomic profile of frailty phenotype.GeroScience · 2021Article
- Thrombospondin 2 Promotes IL-6 Production in Osteoarthritis Synovial Fibroblasts via the PI3K/AKT/NF-κB Pathway.Journal of inflammation research · 2021Article
- Contribution of Thrombospondin-1 and -2 to Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome.Mediators of inflammation · 2021Article
- A single cell transcriptional atlas of early synovial joint development.Development (Cambridge, England) · 2020Article
- Role of thrombospondin‑1 and thrombospondin‑2 in cardiovascular diseases (Review).International journal of molecular medicine · 2020Review
- Integrated Transcriptomic and Proteomic Analyses of the Interaction Between Chicken Synovial Fibroblasts andFrontiers in microbiology · 2020Article
- Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis.Microcirculation (New York, N.Y. : 1994) · 2016Review
- Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-/- mice by targeting the TGFβ-Smad3 pathway.Journal of lipid research · 2015Article
- Thrombospondin-2 and extracellular matrix assembly.Biochimica et biophysica acta · 2014Review
- Putative effects of potentially anti-angiogenic drugs in rheumatic diseases.European journal of clinical pharmacology · 2014Review
- Targeting the synovial angiogenesis as a novel treatment approach to osteoarthritis.Therapeutic advances in musculoskeletal disease · 2014Review
- Macrophages and angiogenesis in rheumatic diseases.Vascular cell · 2013Article
- Long-term gene therapy with thrombospondin 2 inhibits TGF-β activation, inflammation and angiogenesis in chronic allograft nephropathy.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Thrombospondin 2 (TSP2), a matricellular protein with a primary role in modulating cell-matrix interactions, has been implicated in tissue repair and foreign body responses. Here we show that TSP2 has regulatory function in the chronic inflammatory lesions of rheumatoid arthritis. Tissue TSP2, produced by synovial fibroblasts, endothelial cells, and macrophages correlated not only with the intensity of angiogenesis but also with the architecture of lymphoid infiltrates. Synovial tissues with diffuse inflammatory infiltrates had high levels of TSP2, whereas synovial tissues with ectopic germinal center reactions and T cell-B cell aggregates produced low levels. Cell-based gene therapy with TSP2 was used to examine the in vivo effects of the matrix protein on neoangiogenesis and lymphoid organization. Human synovium-severe combined immunodeficiency (SCID) mouse chimeras were treated with TSP2-transfected fibroblasts deposited into the peritoneum. Overexpression of TSP2 led to the accumulation of TSP2 protein in the inflamed synovium and resulted in a prompt inhibition of lesional vascularization. Beside its anti-angiogenic activity, TSP2 also suppressed the production of the proinflammatory mediators, interferon-gamma and tumor necrosis factor-alpha, and induced the depletion of tissue-residing T cells. We propose that TSP2 is an endogenous regulator of angiogenesis and autoimmune inflammation in the synovium and represents a protective mechanism preventing ectopic lympho-organogenesis and persistent inflammation in this tissue site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.